GSK's Twice-Yearly Anti-IL-5 Antibody Exdensur Approved by FDA, Transforming Severe Asthma Treatment

Dec 18, 2025 10:18 CST Updated 10:18

GSK

Pharmaceutical R&D Manufacturer

Abstract:The U.S. FDA approved GSK's anti-IL-5 antibody drug Exdensur on December 17, 2025, for the treatment of patients aged 12 years and older with severe eosinophilic asthma. This ultra-long-acting biologic agent...Once every six months dosingFrequency breaks traditional treatment patterns, and Phase III clinical trials show it can significantly reduce the risk of acute asthma attacks, offering a new option for severe patients. However, the drug's indication for nasal polyp-type chronic sinusitis has not been approved, and GSK stated that it will continue to communicate with regulatory authorities.

Core Indications Approved, Dosing Frequency Highlights

The approval of Exdensur was primarily based on positive data from two pivotal Phase III clinical trials —— SWIFT-1 and SWIFT-2. The results of these two studies were published in the New England Journal of Medicine in September 2024. The SWIFT-1 trial showed that the drug reduced patients' annual rate of severe asthma exacerbations by 58%, while the treatment effect in the SWIFT-2 trial reached 48%.

Notably, this drug is administered via subcutaneous injection once every six months, making it one of the few ultra-long-acting biologics in the field of asthma treatment. Kaivan Khavandi, Global Head of Respiratory, Immunology, and Inflammation Research and Development at GSK, stated that U.S. doctors can now offer continuous protection against acute exacerbations for patients with severe asthma, and Exdensur is expected to redefine the clinical care standard for this indication.

In terms of safety, late-stage clinical trial data showed that Exdensur was well-tolerated, with comparable incidence and severity of adverse events between the treatment and placebo groups, and no significant safety concerns were identified.

Precise Mechanism of Action, Targeting the Root of Inflammation

The core mechanism of Exdensur is to block the IL-5 cytokine, a key molecule involved in the differentiation, growth, activation, and survival of eosinophils. As a type of white blood cell, eosinophils are crucial participants in the inflammatory response of asthma. By precisely targeting this pathological link, the drug can alleviate the inflammatory process of asthma at its root, rather than merely controlling symptoms.

This targeted mode of action allows Exdensur to demonstrate unique advantages in critically ill patients. For patients with severe eosinophilic asthma who respond poorly to traditional treatments and experience frequent exacerbations, this drug offers a more fundamental treatment option, with the potential to reduce reliance on rescue medications and improve quality of life.

Indication Expansion Faces Obstacles, Multi-Field R&D Continues to Advance

Despite the smooth approval of the asthma indication, the FDA did not approve Exdensur for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). GSK submitted data from two Phase III trials, ANCHOR-1 and ANCHOR-2, for this indication, which showed that the drug significantly outperformed placebo in terms of nasal polyp score and improvement in nasal obstruction symptoms.

Interestingly, the UK Medicines and Healthcare products Regulatory Agency approved Exdensur on Monday for two indications simultaneously: asthma and chronic rhinosinusitis with nasal polyps. A GSK spokesperson stated that they will continue to communicate with the FDA to push for the approval of this indication in the United States.

Moreover, GSK is still expanding the therapeutic boundaries of Exdensur. The drug is currently in late-stage clinical trials for various inflammatory diseases, including chronic obstructive pulmonary disease, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome, with the potential to cover a broader patient population in the future.

The approval of this new asthma drug not only brings a more convenient and long-acting treatment option for severe patients but also highlights the R&D breakthrough of biologics in the field of respiratory diseases. With the advancement of multi-indication research, Exdensur is expected to become one of GSK's core products in the immunoinflammatory field.

Reference Source:https://www.biospace.com/fda/gsk-wins-asthma-approval-for-anti-inflammatory-antibody

Scan the WeChat QR code, add the editor of the Biological Products Circle, and those who meet the requirements can join.
Biological Products WeChat Group!
Please indicate: Name + Research Direction!

Edition
Authority
Sound
Bright

All reproduced articles in this official account are intended to convey more information, with the source and author clearly stated. Media or individuals who do not wish to be reprinted may contact us (cbplib@163.com), and we will immediately proceed with deletion. All articles represent the views of the author and not this site.